UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    05

    UCB Showcases Key Rheumatology Data at ACR Convergence 2021

    Read More Share:linkedin| twitter| email

    Oct

    27

    Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

    Read More Share:linkedin| twitter| email

    Oct

    16

    Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

    Read More Share:linkedin| twitter| email

    Sep

    29

    New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

    Read More Share:linkedin| twitter| email

    Aug

    30

    UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

    Read More Share:linkedin| twitter| email

    Apr

    28

    UCB Announces PDUFA Date for Bimekizumab

    Read More Share:linkedin| twitter| email

    Apr

    23

    "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    Apr

    23

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

    Read More Share:linkedin| twitter| email

    Feb

    25

    UCB - Sustaining Growth, Now and Into the Future

    Read More Share:linkedin| twitter| email

    Dec

    03

    UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

    • 15 scientific presentations highlight data on BRIVACT® (brivaracetam) CV, NAYZILAM® (midazolam) nasal spray CIV, VIMPAT® (lacosamide) CV, and others, illustrating UCB’s commitment to developing new treatment options for patients in their treatment journey
    • UCB’s VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel
    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)